



Contents

PHARMACEUTICAL DEVELOPMENT

<i>Table of Contents</i>	VI
<i>Acronyms - Abbreviations</i>	XIII
Introduction	XV
Preface	XVI
Forward	XVII


Chapter 1

R egulatory	1.1
- Pre-formulation checklist	1.3
D ocumentation	1.4
- Getting the Right Documentation	1.5
D evelopment Notebooks	1.8
- Development Notebooks checklist	1.10
- SOP Control and Development Notebooks SOPs	1.11


Chapter 2

D eveloping the Formula -A CR Overview	2.1
- Development Flowchart	2.4
D evelopment CR Formula Checklist	2.5
D evelopment Formula CR	2.6
U sing a typical IVIV Model - typical IVIVC Models	2.7
C hoosing IVIVC levels	2.8
CR Formula development Checklist	2.9
P roduct Development SOPs List	2.11
D eveloping the Formula	2.13
P roduct Development Flow Chart	2.19
P roduct Development Tabulated Chart (24 Stages)	2.21
CR Formula development SOP Checklist	2.29
P urified Water - An essential ingredient	2.31
D o and D on'ts in Development	2.34
P urified Water - Checklist	2.35

Contents



Chapter	3	
Active Ingredients		3.1
-Do's and Don'ts		3.2
-Active Checklist		3.3
-Approved Suppliers Checklist		3.5
-Standard Operating Procedures, Actives		3.6
-Alternative Pharmaceutical Sources		3.7
Chapter	4	
Semi active ingredients		4.1
-Validating the Semi-active ingredients, Checklist		4.3
Non Active Excipients		4.4
Non Active general scheme		4.8
Non Active release controlling excipients		4.10
Non Active excipients checklist		4.11
Qualifying the Antioxidant		4.13
Antioxidant Tabulations		4.14
Chapter	5	
Container closure systems		5.1
-Container-liner-closure systems, Checklist		5.2
-Container-liner-closure systems, SOPs		5.4
-Packaging Components		5.5
-Packaging Components Documentation Requirements SOP		5.6
-Packaging Components Test Requirements		5.16
Chapter	6	
Manufacturing Instructions		6.1
- Manufacturing Instructions; Checklist		6.4
- The manufacturing Instructions and Controls		6.5
- Master Formula		6.6
- Manufacturing Flow Charts		6.18
Chapter	7	
In-process Quality Controls		7.1
-Manufacturing in-process controls; Checklist		7.2
-In-process Quality Controls - overview		7.5
-In-process Quality Controls - production		7.6
-In-process Quality Controls - quality control		7.7
-In-process Quality Controls - specification - bulk		7.8
-In-process Quality Controls - specification - cores		7.9
-In-process Quality Controls - specification - coated		7.10




Contents

Chapter	8	
Finished Product Specifications		8.1
- Finished Product Specifications Release Checklist		8.2
- Finished Product Specifications Stability Checklist		8.3
- Finished Product Specifications; Required SOPs		8.6
Chapter	9	
Process Optimization and Procedures		9.1
Qualification of Antioxidant and Lubricant		9.3
Optimization Limits		9.5
Process Optimization flow Chart		9.7
Chapter	10	
Scale-up Procedures		10.1
- Scale-up procedures; checklist		10.5
- Scale-up procedures; SOPs		10.6
Chapter	11	
Cleaning Limits		11.1
Cleaning Limits Procedures; Checklist		11.6
Cleaning Validation Requirements; SOPs		11.8
Cleaning Procedures; As the FDA see it.		11.9
Chapter	12	
Analytical Validation Requirements		12.1
-Analytical Testing Out of Specification		12.21
-Analytical Testing Do's and Don'ts		12.23
Analytical Testing Out of Specification		12.27
-Ruggedness and Robustness		12.37
-Impurities in Drug Substances		12.41
-Impurities Do's and Don'ts		12.50
-Impurities Glossary of terms		12.52
-Impurities Decision Trees		12.53
Analytical Post approval Changes -PAC-ALTS		12.55
PAC-ALTS Checklist		12.58
Chapter	13	
Process Qualification Batch		13.1
-Process Qualification Batch; Checklist		13.2
-Process Qualification Batch; SOPs		13.3
-Process Qualification Blend Analysis		13.5
-Process Qualification Blend Analysis - Do's and Don'ts		13.7
-Process Qualification - Qualifying Tablet Hardness		13.9
Tablet Hardness Protocol		13.10



Contents

Chapter	14	
Pivotal batch		
-The Pivotal Batch		14.1
-Pivotal batch Checklist		14.2
-Pivotal batch SOPs		14.3
-Sampling and Testing the Pivotal Batch		14.5
-Auditing the Pivotal batch		14.10
-Auditing the Pivotal batch Checklist		14.11
Chapter	15	
BA & BE Overview		15.1
Bioequivalence vs. Reference Listed Drug		15.27
Statistical Bioequivalence		15.30
Test Designs - Overview		15.38
IBE Equation explained		15.40
IBE Big Picture (Pros and Cons)		15.41
Comparing IBE and ABE		15.42
Dissolution Testing in MR Dosage Forms		15.43
Model Two and three way studies		15.44
BA-BE Food-Effects in BA-BE Studies		15.48
Food-Effects in BA-BE Studies		15.50
Side-by-side comparison		15.55
Bioanalytical Methods		15.56
Biopharmaceutics Classification System		15.72
Generic Drug Dissolution and RLD		15.88
Performance Verification in Dissolution testing & IQOQ		15.95
Similarity Testing - Chow, Pitt and Others		15.123
Similarity Factor in dissolution testing		15.127
Chapter	16	
Technical Transfer Documentation		16.1
-Technical Transfer Documentation; TTD		16.2
-Technical Transfer Documentation; Checklist		16.5
-Technical Transfer Documentation; Pharmaceutical Part		16.7
-Technical Transfer Documentation; Analytical Part		16.11
Chapter	17	
Process Validation batches		17.1
-The Process Validation Batches; checklist		17.2
-Process Validation Requirements; SOPs		17.4
-Process Validation Master Plan		17.5
-Prospective Validation Protocol		17.8



Contents

Chapter

18

Pre--Approval Inspections	18.1
PAI Summary	18.8
Pre--Approval Inspection Audit - Team Set Up	18.9
Pre--Approval Inspection Audit - Team Activities	18.10

Chapter

19

Stability Testing of Drug Substance and Drug Product I	19.1
Stability Testing of Drug Substance and Drug Product II	19.15
Stability Testing of Drug Substance and Drug Product III	19.21
Stability Testing Significant Change	19.24
Stability Testing Significant SOP	19.25
Storage Conditions	19.29
Setting up a functional Stability Unit	19.31
Photostability in New Drug Products	19.39
Photostability Flowchart	19.47
Stability SOPs Development	19.49


Chapter

20

Standard Operational Procedures

Development SOPs	20.1
Index of Pharmaceutical Standard Operating Procedures	20.3
Index of Analytical Standard Operating Procedures	20.11
Index of Microbiological Standard Operating Procedures	20.19
Index of Stability Standard Operating Procedures	20.23

Handbook of Pharmaceutical
Generic Development Series



ISSN 0793 8772

*An on-going Handbook Series
Additional Volumes in Preparation*

ISSN 0793 8640 - Electronic Version
Handbook Development 24 Volume Series
ISSN Series Number 0793 7792 - Electronic Version.

EDITORIAL PREFACE

Handbook of Generic Development - Oral Tablet Dosage Form


This expanded International Edition of the Handbook **24** volume series of the Ongoing of Generic Drug Development and appears under the cumulative title of the Handbook Series of Generic Drug Development. The ongoing series is updated annually at the end of each year. This is an ongoing process as new data, specifications and process techniques are added on a continual and expanding basis. This handbook is continually updated and revised, as each new annual edition brings an enlarged and extended profile in the drug development process, as well as new agency rules, guidelines and guidance to industry which continue to be added year by year as the global product data base expands. Currently over 150 scientific publications and drug development conferences are annually referenced in the **24** volume Handbook series of Generic Drug Development.

This mammoth task presents a continual ongoing commitment by the scientific review committee to the improvement of the technical databases and the product specific drug development requirements and know-how technology accessed through the world wide IAGIM joint ventures and know-how projects currently active in over 15 countries.

The Handbook is available in electronic format (CD ROM) and the e-format is up-dated annually to association members of IAGIM.

This international edition of the Handbook is redesigned to meet the latest - Guidance for Industry - Organization of an Abbreviated New Drug Application as well as all key draft and final FDA guidelines and requirements of the Center of Drug Evaluation and Research (CDER - OGD 1)

- Editor-in-Chief.



ISSN 0793 8632

An On-going Series

Additional Volumes in Preparation

General Drug Development Series ISSN 0973 7601

Electronic Drug Development Series ISSN 0973 761X

ÓŠĪ

International Print Edition

pLocum±Pressp

© COPYRIGHT

Ī > Đ